Baird Reiterates Outperform on Affymax, Inc. with $20 Price Target
Tweet Send to a FriendGet Alerts AFFY Hot Sheet
Price: $1.45 +14.17%
Rating Summary:
6 Buy, 4 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
6 Buy, 4 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade AFFY Now!
Today analysts at Baird reiterated their Outperform rating on Affymax, Inc. (NASDAQ: AFFY) and moved their price target to $20.00.
“With Omontys launching late April, full sales capability not on-line till late June, and dialysis uptake notoriously slow, low Q212 expectations were validated,” said analysts. “However, with revelations of numerous MDO/SDO contracts (only one of which identified by name) and Fresenius conversion happening much faster than we had thought, we think Omontys may yet measurably beat our $20.6M FY12 estimate.”
For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.
Shares of Affymax, Inc. closed at $16.99 yesterday, with a 52 week range of $3.93-$17.33.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
“With Omontys launching late April, full sales capability not on-line till late June, and dialysis uptake notoriously slow, low Q212 expectations were validated,” said analysts. “However, with revelations of numerous MDO/SDO contracts (only one of which identified by name) and Fresenius conversion happening much faster than we had thought, we think Omontys may yet measurably beat our $20.6M FY12 estimate.”
For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.
Shares of Affymax, Inc. closed at $16.99 yesterday, with a 52 week range of $3.93-$17.33.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Best Buy (BBY) May Show Progress on Earnings Front, UBS Remains Neutral
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Robert W Baird
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
